Most notably, while NPM1 mutation was labeled as favorable in 2017 ELN (especially when FLT3-ITD allelic ratio was low), NPM1 mutation was classified as part of “myeloid.gene.R”–a poor-prognosis cluster for AML–according to the Pan-Myeloid Axis. This evidence concerns the gene FLT3 and acute myeloid leukemia.